BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Genetown

  The Next Biotech ‘Unicorn,’ Ginkgo Bioworks, Just Nabbed Another $275M

  Ginkgo Bioworks, recently recognized by Forbes as one of 25 U.S. companies likely to hit a valuation of $1B or more, is well on its way.

  December 14, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Pharm Country

  This is the Drug That Could Kick Regeneron’s Stock Into Gear

  Regeneron shares have made little headway since the disappointing launch of Praluent in 2015.

  December 14, 2017

   · 

  1 min read
• 

  Business

  GRAIL Poaches New CEO From Roche, Genentech

  Four months after Jeff Huber stepped down as CEO of GRAIL, the company has tapped his replacement.

  December 14, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Genetown

  Sanofi Genzyme Recalls Contaminated Arthritis Gel

  A lot containing 18,000 gel-filled syringes of Sinvisc-One tested positive for microbial contamination.

  December 14, 2017

   · 

  1 min read
• FDA

  Karolinska Development’s Portfolio Company Promimic Receives FDA Approval for HAnano Surface for Use on Dental Implants

  The approval of HAnano Surface in the United States has been executed in accordance with the new 510(k) legislation for medical devices.

  December 14, 2017

   · 

  1 min read
• 

  Genetown

  AbbVie, Pfizer Jump in on Newly-Launched Jnana Therapeutics’ $50M Funding Round

  Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

  December 14, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Merck’s Ace Keytruda Flunks Key Phase III Stomach Cancer Study

  Merck’s Keytruda came up short in a pivotal Phase III trial as a second-line treatment for patients with advanced gastricadenocarcinoma or GEJ adenocarcinoma.

  December 14, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Asklepios BioPharma Launches New Biotech Actus Therapeutics

  Asklepios BioPharma is forming a new biotech portfolio company, Actus Therapeutics.

  December 14, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Little reMYND Forges 350M+ Euros Tie-Up With Drug Giant Novo Nordisk

  reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.

  December 14, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Genetown

  Kyn Therapeutics Banks $49M to Advance Cancer Immunometabolism Therapies

  Investors were Atlas Venture and OrbiMed.

  December 14, 2017

   · 

  2 min read

   · 

  Mark Terry